170 related articles for article (PubMed ID: 21246003)
1. Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
Kim SO; Han SY; Baek YH; Lee SW; Han JS; Kim BG; Cho JH; Nam KJ
World J Gastroenterol; 2011 Jan; 17(2):267-70. PubMed ID: 21246003
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Keating GM; Santoro A
Drugs; 2009; 69(2):223-40. PubMed ID: 19228077
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
[TBL] [Abstract][Full Text] [Related]
4. Colon perforation during sorafenib therapy for advanced hepatocelluar carcinoma. A case report.
Park SG; Chung CH; Park CY
Tumori; 2011; 97(6):794-9. PubMed ID: 22322848
[TBL] [Abstract][Full Text] [Related]
5. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
[No Abstract] [Full Text] [Related]
6. Sorafenib in advanced hepatocellular carcinoma.
Spinzi G; Paggi S
N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
[No Abstract] [Full Text] [Related]
7. [The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Takashima T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2676-8. PubMed ID: 21224677
[TBL] [Abstract][Full Text] [Related]
8. [Hepatocellular carcinoma - long-term treatable disease].
Fínek J
Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
[TBL] [Abstract][Full Text] [Related]
9. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
Daniele B; Di Maio M
J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
[No Abstract] [Full Text] [Related]
10. All that glitters: sorafenib.
Abbass K; Dewani S; Markert R; Kaplon MK; Baumann MA
Intern Med; 2011; 50(7):797. PubMed ID: 21467725
[No Abstract] [Full Text] [Related]
11. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.
Dogan E; Aksoy S; Arslan C; Dede DS; Altundag K
Med Oncol; 2010 Dec; 27(4):1436-7. PubMed ID: 20012235
[No Abstract] [Full Text] [Related]
12. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
[TBL] [Abstract][Full Text] [Related]
13. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Alexandrescu DT; McClure R; Farzanmehr H; Dasanu CA
J Clin Oncol; 2008 Aug; 26(24):4047-8. PubMed ID: 18711201
[No Abstract] [Full Text] [Related]
14. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
Vincenzi B; Santini D; Russo A; Addeo R; Giuliani F; Montella L; Rizzo S; Venditti O; Frezza AM; Caraglia M; Colucci G; Del Prete S; Tonini G
Oncologist; 2010; 15(1):85-92. PubMed ID: 20051477
[TBL] [Abstract][Full Text] [Related]
15. [Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Xu L; Li P; Lin XJ; Yuan YF; Zhang YQ; Chen MS
Zhonghua Zhong Liu Za Zhi; 2009 Jan; 31(1):58-61. PubMed ID: 19538872
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
Rombolà F; Caravetta A; Mollo F; Spinoso A; Peluso L; Guarino R
Acta Medica (Hradec Kralove); 2011; 54(4):177-9. PubMed ID: 22283115
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S; Nakajima K
Cancer Sci; 2008 Jan; 99(1):159-65. PubMed ID: 17953709
[TBL] [Abstract][Full Text] [Related]
19. A case of variant angina in a patient under chronic treatment with sorafenib.
Porto I; Leo A; Miele L; Pompili M; Landolfi R; Crea F
Nat Rev Clin Oncol; 2010 Aug; 7(8):476-80. PubMed ID: 20479781
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib: in hepatocellular carcinoma.
Simpson D; Keating GM
Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
